Page 13 - Managing Advanced Urothelial Carcinoma in 2020: Canadian Consensus Updates

Second-line chemotherapy for urothelial carcinoma

Vinflunine: Taxanes:
• Survival longer in eligible phase III population • Nonrandomized phase II trials (Roth et al;

• Required 1 prior platinum-based line for Mcaffrey et al)
metastatic disease

• PS 0-1

Drug N RR % Median PFS Median OS

Paclitaxel 31 10 2.2 7.2

Docetaxel 30 13 - 9.0

Bellmunt J et al. JCO 2009;27:4454-4461 Sonpavde, Lancet Oncol 2010